SCHEMBL268017

SCHEMBL268017

COC(=O)c1cc(C)sc1NC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
ALDH1A1 P00352 7/20 0.63
MAPT P10636 5/20 0.63
HPGD P15428 5/20 0.63
GAA P10253 1/20 0.63
HTT P42858 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
KMT2A Q03164 4/20 0.62
LMNA P02545 2/20 0.60
FLT3 P36888 4/20 0.58
POLB P06746 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PKM P14618 2/20 0.53
RXFP1 Q9HBX9 1/20 0.51
MEN1 O00255 3/20 0.50
RECQL P46063 1/20 0.50
TP53 P04637 1/20 0.50
CHEK1 O14757 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5788877 0.90 MAPT (0.60) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL267990 0.84 KDM4E (0.58) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL266561 0.84 KMT2A (0.58) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL267190 0.81 FLT3 (0.81) KDM4EALDH1A1MAPTHPGDTDP1
SCHEMBL267632 0.80 ALDH1A1 (0.56) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL8200517 0.80 SMN1; SMN2 (0.53) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL268458 0.78 FLT3 (0.65) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL7892988 0.76 NR1H4 (0.58) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL266327 0.75 CHEK1 (0.80) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL21411364 0.74 SMN1; SMN2 (0.61) KDM4EALDH1A1MAPTHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885ALDH1A1 3022/4885MAPT 4195/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885ALDH1A1 2872/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.